Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
SPECIALTY GUIDELINE MANAGEMENT LUPRON DEPOT 3.75 mg LUPRON DEPOT-3 MONTH 11.25 mg (leuprolide acetate for depot suspension) POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. FDA-Approved Indications • Endometriosis o Lupron Depot 3.75 mg and Lupron Depot-3 Month 11.25 mg are indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions. Lupron Depot 3.75 mg monthly and Lupron Depot-3 Month 11.25 mg (with norethindrone acetate 5 mg daily) are indicated for initial management of endometriosis and for management of recurrence of symptoms. Duration of initial treatment and retreatment should be limited to six months each and use is not recommended longer than a total of 12 months. • Uterine Leiomyomata (Fibroids) o When used concomitantly with iron therapy, Lupron Depot 3.75 mg and Lupron Depot-3 Month 11.25 mg are indicated for the preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata. The clinician may wish to consider a one-month trial period on iron alone inasmuch as some of the patients will respond to iron alone. Lupron may be added if the response to iron alone is considered inadequate. Recommended duration of therapy is up to 3 months, either given as Lupron Depot 3.75 mg monthly or as a single injection of Lupron Depot-3 Month 11.25 mg. The Lupron Depot-3 Month 11.25 mg is indicated only for women for whom three months of hormonal suppression is deemed necessary. Experience with Lupron Depot in females has been limited to women 18 years of age and older, and experience with the Lupron Depot-3 Month 11.25 mg formulation is limited to treatment for no longer than six months. Compendial Uses • Ovarian cancer: o Ovarian stromal tumors: for clinical relapse in patients with stage II-IV granulosa cell tumors o Epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer (3.75 mg only): as a single agent for persistent disease or recurrence • Breast cancer (Lupron Depot 3.75 mg only) : o As a consideration with adjuvant endocrine therapy in premenopausal women with hormone receptorpositive disease o In combination with endocrine therapy for premenopausal women with hormone receptor-positive recurrent or metastatic disease • Preoperative use for uterine leiomyomata (fibroids) to facilitate surgery All other indications are considered experimental/investigational and are not a covered benefit. B. EXCLUSIONS • Pregnancy • Breastfeeding • Undiagnosed abnormal vaginal bleeding Lupron Depot Endometriosis-Fibroids SGM P2014.doc © 2014 Caremark. All rights reserved. This document contains confidential and proprietary information of CVS/caremark and cannot be reproduced, distributed or printed without written permission from CVS/caremark. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark. 1 C. CRITERIA FOR APPROVAL 1. Endometriosis Authorization of 6 months (one treatment course) may be granted to adult female members for initial treatment of endometriosis who have not received previous therapy with Lupron Depot or Lupaneta Pack. 2. Uterine fibroids Authorization of 3 months (one treatment course) may be granted to adult female members for initial treatment of uterine fibroids who have not received previous therapy with Lupron Depot when EITHER of the following criteria is met: a. The member has a diagnosis of anemia (Hct ≤ 30% and/or Hgb ≤ 10 g/dL) AND Lupron Depot will be used in conjunction with iron therapy b. Lupron Depot will be used in the preoperative setting to facilitate surgery 3. Ovarian cancer 3.1. Ovarian stromal tumor Authorization of 12 months may be granted to adult female members for initial treatment of ovarian stromal tumor. 3.2. Epithelial ovarian cancer Authorization of 12 months may be granted to adult female members who are prescribed Lupron Depot 3.75 mg as a single agent for persistent or recurrent epithelial ovarian cancer. 4. Fallopian tube cancer Authorization of 12 months may be granted to adult female members who are prescribed Lupron Depot 3.75 mg as a single agent for persistent or recurrent fallopian tube cancer. 5. Primary peritoneal cancer Authorization of 12 months may be granted to adult female members who are prescribed Lupron Depot 3.75 mg as a single agent for persistent or recurrent primary peritoneal cancer. 6. Breast cancer Authorization of 12 months may be granted to premenopausal adult female members who are prescribed Lupron Depot 3.75 mg for hormone receptor positive breast cancer. D. CONTINUATION OF THERAPY 1. Endometriosis Authorization of 6 months (one treatment course) may be granted to adult female members for retreatment of endometriosis who have received previous therapy with Lupron Depot or Lupaneta Pack for ≥ 6 months but < 12 months when ALL of the following criteria are met: a. The member had a recurrence of symptoms b. The member has a bone mineral density within normal limits c. The member will be receiving add-back therapy (e.g., norethindrone) 2. Uterine Fibroids Authorization of 3 months (one treatment course) may be granted to adult female members for retreatment of uterine fibroids who have received previous therapy with Lupron Depot for less than 6 months AND have documentation of bone mineral density within normal limits and EITHER of the following criteria is met: a. The member has a diagnosis of anemia (Hct ≤ 30% and/or Hgb ≤ 10 g/dL) AND Lupron Depot will be used in conjunction with iron therapy b. Lupron Depot will be used in the preoperative setting to facilitate surgery 3. Ovarian cancer, fallopian tube cancer, primary peritoneal cancer, breast cancer All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria. Lupron Depot Endometriosis-Fibroids SGM P2014.doc © 2014 Caremark. All rights reserved. This document contains confidential and proprietary information of CVS/caremark and cannot be reproduced, distributed or printed without written permission from CVS/caremark. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark. 2 E. DOSAGE AND ADMINISTRATION Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. 1. Dosing Limits The following dosing limits apply to all approvable diagnoses: • Maximum dose of Lupron Depot is 3.75 mg per month REFERENCES 1. Lupron Depot 3.75 mg and Lupron Depot-3 Month 11.25 mg [package insert]. North Chicago, IL: AbbVie Inc.; October 2013. 2. The NCCN Drugs & Biologics Compendium™ © 2014 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed May 1, 2014. 3. Micromedex Solutions [database online]. Ann Arbor, MI: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed May 28, 2014. 4. Marret H, Fritel X, Ouldamer L, et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2012;165:156-164. 5. Alternatives to hysterectomy in the management of leiomyomas. ACOG Practice Bulletin No. 96. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2008;112:387-400. Lupron Depot Endometriosis-Fibroids SGM P2014.doc © 2014 Caremark. All rights reserved. This document contains confidential and proprietary information of CVS/caremark and cannot be reproduced, distributed or printed without written permission from CVS/caremark. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark. 3